Table 3. Adverse events occurring in greater than 5% of patients in any study group.
| Adverse Event Preferred Term | WR 279,396 (n = 201) |
Paromomycin (n = 198) |
|---|---|---|
| Contact Dermatitis | 90 (44.8) | 89 (44.9) |
| Nasopharyngitis | 90 (44.8) | 82 (41.4) |
| Pruritus | 54 (26.9) | 50 (25.3) |
| Headache | 28 (13.9) | 19 (9.6) |
| Lymphangitis | 23 (11.4) | 14 (7.1) |
| Skin erosion | 22 (10.9) | 11 (5.6) |
| Bacterial Superinfection | 19 (9.5) | 19 (9.6) |
| Application site injury | 19 (9.5) | 34 (17.2) |
| Application site dermatitis | 19 (9.5) | 13 (6.6) |
| Arthropod bite | 17 (8.5) | 14 (7.1) |
| Application site pain | 14 (7.0) | 16 (8.1) |
| Rhinitis | 12 (6.0) | 13 (6.6) |
| Application site pruritus | 11 (5.5) | 8 (4.0) |
| Folliculitis | 7 (3.5) | 13 (6.6) |
| Lymphadenopathy | 6 (3.0) | 10 (5.1) |